高级检索

    瑞马唑仑联合纳布啡在肥胖患者无痛肠镜检查中的应用

    Application of remimazolam combined with nalbuphine for painless colonoscopy in obese patients

    • 摘要: 目的 评价瑞马唑仑联合纳布啡用于肥胖患者肠镜检查的安全性和有效性。方法 选取2024年2月—7月在徐州医科大学第二附属医院行无痛肠镜检查的肥胖患者90例,随机分为丙泊酚联合纳布啡组(PN组)和瑞马唑仑联合纳布啡组(RN组),每组45例。记录2组患者麻醉开始前(T1)、内镜进入肛门时(T2)、内镜进入肝曲时(T3)、内镜到达回盲部时(T4)及检查结束时(T5)的平均动脉压(MAP)、心率(HR)和脉搏氧饱和度(SpO2);记录麻醉起效时间、肠镜检查时间、苏醒时间及PACU停留时间,以及改良警觉/镇静(MOAA/S)评分、改良行为疼痛评分(BPS-NI)>5分、不良反应和患者满意度;记录2组患者术后恢复质量(QoR-15)量表评分。结果 RN组低氧血症发生率(11.11%)低于PN组(37.78%)(P<0.05),RN组患者T2—T5时点的SpO2和MAP明显高于PN组(P<0.05)。与PN组相比,RN组的苏醒时间和PACU停留时间均显著缩短(P<0.001),且重度低氧血症、低血压、头晕及注射痛发生率明显降低(P<0.05)。2组患者MOAA/S评分和BPS-NI>5分发生率差异无统计学意义(P>0.05)。RN组患者术后QoR-15评分和满意度高于PN组(P<0.05)。结论 瑞马唑仑联合纳布啡用于肥胖患者肠镜检查,与丙泊酚联合纳布啡相比安全有效且苏醒更快,不良反应更少,术后恢复质量更高。

       

      Abstract: Objective To evaluate the safety and effectiveness of remimazolam combined with nalbuphine for painless colonoscopy in obese patients. Methods Ninety obese patients who underwent painless colonoscopy at the Second Affiliated Hospital of Xuzhou Medical University from February to July 2024 were selected. They were randomly divided into two groups (n=45): propofol combined with nalbuphine (group PN) and remimazolam combined with nalbuphine (group RN). The mean arterial pressure (MAP), heart rate (HR), and pulse oxygen saturation (SpO2) were recorded before anesthesia (T1), at the time the endoscope entered the anus (T2), at the time the endoscope reached the hepatic flexure (T3), at the time the endoscope reached the cecum (T4), and at the end of the examination (T5). The onset time of anesthesia, colonoscopy duration, emergence time, and the length of PACU stay were recorded. Furthermore, the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score, Behavioral Pain Scale-Non Intubated (BPS-NI) score >5, adverse reactions, and patient satisfaction were recorded. The postoperative recovery quality was assessed using the QoR-15 scale. Results The incidence of hypoxemia in group RN (11.11%) was lower than in group PN (37.78%) (P<0.05). From T2 to T5, the SpO2 and MAP of group RN were significantly higher than those of group PN (P<0.05). Compared with group PN, group RN showed significantly reduced emergence time and shortened length of PACU stay (P<0.001), with decreased incidences of severe hypoxemia, hypotension, dizziness, and injection pain (P<0.05). There were no significant differences between the two groups in terms of MOAA/S score and BPS-NI >5 score (P>0.05). The postoperative QoR-15 score and patient satisfaction in group RN were higher than those in group PN (P<0.05). Conclusions Compared with propofol-nalbuphine, remimazolam-nalbuphine combination demonstrates superior safety and effectiveness for colonoscopy in obese patients, with shortened emergence time, reduced adverse events, and improved postoperative recovery quality.

       

    /

    返回文章
    返回